Previous 10 | Next 10 |
Exelixis, Inc. (EXEL) Q1 2019 Earnings Conference Call May 1, 2019 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President-Public Affairs and Investor Relations Mike Morrissey – President and Chief Executive Officer Chris Senner – Chief Finan...
Exelixis (NASDAQ: EXEL ) Q1 results ($M): Revenues: 215.5 (+0.8%); product sales: 179.6 (+33.7%); collaborations: 35.9 (-54.8%). More news on: Exelixis, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Exelixis (NASDAQ: EXEL ): Q1 Non-GAAP EPS of $0.27 beats by $0.05 ; GAAP EPS of $0.24. Revenue of $215.45M (+0.8% Y/Y) beats by $9.39M . Press Release More news on: Exelixis, Inc., Earnings news and commentary, Healthcare stocks news,
– COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors – Exelixis, Inc. (NASDAQ: EXEL) today announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in...
- Total Revenue of $215.5 Million, Cabozantinib Franchise Revenue of $179.6 Million - - GAAP Diluted EPS of $0.24, Non-GAAP Diluted EPS of $0.27 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported financial resul...
Exelixis (NASDAQ: EXEL ) is scheduled to announce Q1 earnings results on Wednesday, May 1st, after market close. The consensus EPS Estimate is $0.22 (-40.5% Y/Y) and the consensus Revenue Estimate is $206.06M (-3.0% Y/Y). Over the last 2 years, exel has beaten EPS estimates 88% of th...
Exelixis (NASDAQ: EXEL ) announces that licensee Takeda Pharmaceutical Company (NYSE: TAK ) has submitted an application to Japanese regulators seeking approval to manufacture and sell CABOMETYX (cabozantinib) in Japan for unresectable and metastatic renal cell carcinoma. More news on: E...
-- Regulatory submission triggers $10 million milestone payment to Exelixis under collaboration and license agreement with Takeda -- -- Submission based on METEOR and CABOSUN trials as well as Takeda bridging study -- Exelixis, Inc. (Nasdaq: EXEL) today announced that Taked...
Merck ( MRK ) announced that it had received approval in the United States for its Keytruda drug to treat front-line advanced kidney cancer patients. This provides patients with a new treatment option that may help treat their cancer more adequately. On top of that, it's another win for ...
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2019 financial results will be released on Wednesday, May 1, 2019 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...